Sarepta Therapeutics Logo
US8036071004
A1J1BH
SRPT

Sarepta Therapeutics

Previsão

O preço-alvo médio dos analistas é € 19,50 (+60,36%). A mediana é € 18,23 (+49,92%).

Comprar
  31
Manter
  18
Vender
  6

Discussões na comunidade

Ainda não há nenhuma discussão sobre este ativo.

Iniciar discussão

  • Sarepta presents pipeline data and expects gradual recovery for ELEVIDYS

    At the Morgan Stanley Healthcare Conference, Sarepta emphasized that marketed products generate cash flow while the siRNA pipeline supports long‑term growth. CEO Michael Severino noted early signs of stabilization after the safety‑related issues with ELEVIDYS, but expects meaningful commercial improvement only in 2027. Key near‑term catalysts are data from the multiple‑ascending‑dose studies of SRP‑1001 (FSHD) and SRP‑1003 (DM1) in the second half of 2026 and higher dose cohorts in early 2027; the PMO franchise remains robust with high treatment adherence. » Mais em de.investing.com


  • Sarepta Therapeutics appoints Michael Severino as CEO – shares rise in premarket trading

    Sarepta Therapeutics named Dr. Michael Severino as its new CEO effective July 28, 2026; Doug Ingram is stepping down and will remain in an advisory role through the end of 2026. The stock rose about 5.2% in premarket trading, driven by confidence in Severino’s experience at Tessera Therapeutics and AbbVie. Analysts warn of a challenging competitive landscape in Duchenne muscular dystrophy; attention also turns to the expected Q2 results on August 5. The share price was $16.49, well below the 52-week high of $25.32 but recovered from a low of $11.68. » Mais em de.investing.com


  • Sarepta Therapeutics rises after FDA acceptance of sNDA for AMONDYS 45 and VYONDYS 53

    The FDA has accepted the supplemental new drug applications (sNDAs) for AMONDYS 45 (Casimersen) and VYONDYS 53 (Golodirsen) for review and set a PDUFA date of February 28, 2027. The filings rely on the phase-3 ESSENCE study, which did not meet its primary endpoint but showed numerical trends and post‑hoc analyses favoring treatment. The news triggered a share gain of about 6.1% and was supported by Mizuho’s maintained 'Outperform' rating with a $31 price target and a favorable market backdrop. Full approval would remove substantial regulatory uncertainty for the PMO portfolio; the PMO franchise reported net product revenue of $228.6 million in Q1 2026. » Mais em de.investing.com


  • Sarepta Therapeutics stock falls after steep drop in Elevidys sales

    Sarepta Therapeutics reported first-quarter Elevidys sales of $102 million versus $375 million in the year-ago quarter, driven by a restricted approval for ambulatory patients following FDA safety reviews. Total revenue was $730.8 million, down $14.1 million, partly offset by higher collaboration revenue. The stock fell about 10.3% in premarket trading to $122.96. » Mais em de.investing.com


  • Sarepta returns to profitability in Q1 2026 despite commercial realignment

    Sarepta reported a non-GAAP earnings per share of $3.16 for Q1 2026 on revenue of $731 million, significantly beating expectations. The company swung to operating profitability thanks to disciplined cost management and a favorable revenue mix, with collaboration revenues (including $325 million from Roche) making up a large portion of results. ELEVIDYS generated $102 million in sales, PMO products contributed $229 million, and cash and cash equivalents stood at $748 million. Sarepta reaffirmed its 2026 guidance (net product revenue $1.2–1.4 billion) and emphasized that pipeline progress and balance-sheet developments make external capital unnecessary for the time being. » Mais em de.investing.com

Em 2022, Sarepta Therapeutics já distribuiu € 0,26 em dividendos. A última distribuição ocorreu em março de 2022.

Dados financeiros

No último trimestre, Sarepta Therapeutics registou receitas de € 336,68 mi e um ganho líquido de -€ 25,13 mi

(EUR) setembro de 2026
YoY
Receitas 336,68 mi 1,07%
Ganho bruto 170,25 mi 19,63%
Ganho líquido -25,13 mi 83,61%
EBITDA 1,54 mi 101,08%

Dados fundamentais

Métrica Valor
Capitalização bolsista
€ 1,3 bi
Número de ações
107,24 mi
Máximo/mínimo de 52 semanas
€ 22,49 - € 12,08
Dividendos Não
Beta
0,21
PER (PE Ratio)
148,11
PEG (PEG Ratio)
0,30
P/VC (PB Ratio)
0,92
P/V (PS Ratio)
0,73

Perfil da empresa

A Sarepta Therapeutics, Inc., uma empresa biofarmacêutica em fase comercial, dedica-se à descoberta e desenvolvimento de terapêuticas direcionadas ao ARN, terapias genéticas e outras modalidades terapêuticas genéticas para o tratamento de doenças raras. A empresa disponibiliza o EXONDYS 51, uma solução injetável para tratar a distrofia muscular de Duchenne (Duchenne) em doentes com mutação confirmada do gene da distrofina que seja suscetível de salto do exão 51; e o VYONDYS 53, para o tratamento da Duchenne em doentes com mutação confirmada do gene da distrofina que seja suscetível de salto do exão 53. A empresa está também a desenvolver o AMONDYS 45, um candidato a medicamento que utiliza a química de oligómeros morfolino de fosforodiamidato e a tecnologia de salto de exões para saltar o exão 45 do gene da distrofina; o SRP-5051, um PMO conjugado com péptido que se liga ao exão 51 do pré-ARNm da distrofina; o SRP-9001, um programa de terapia genética com micro-distrofina para DMD; e o SRP-9003, um programa de terapia genética para distrofias musculares do cíngulo dos membros. A empresa tem acordos de colaboração com a F. Hoffman-La Roche Ltd; o Nationwide Children's Hospital; a Lysogene; a Duke University; a Genethon; e a StrideBio. A empresa foi constituída em 1980 e tem sede em Cambridge, Massachusetts.

Nome
Sarepta Therapeutics
CEO
Michael E. Severino
Sede Cambridge, ma
EUA
Site
Setor
Cuidados de saúde
Indústria
Biotecnologia
Entrada em bolsa
04/06/1997
Colaboradores 835

Símbolos de ticker

Bolsa Símbolo
NASDAQ
SRPT
London Stock Exchange
0L35.L
Frankfurt
AB3A.F
Düsseldorf
AB3A.DU
London
0L35.L
SIX
AB3A.SW
München
AB3A.MU
Hamburg
AB3A.HM
Milan
1SRPT.MI
🍪

Parqet  utiliza cookies. Saber mais